After more than two decades of providing outstanding cancer care to the people of New Jersey, Memorial Sloan Kettering announced today that its newest outpatient treatment center, in Bergen County, will welcome new patients in the coming weeks. In recognition of its debut, MSK’s leadership, joined by members of the community and local elected officials, gathered at the Montvale site to unveil MSK Bergen, a sleek, modern, technology-filled 110,000-plus-square-foot clinical program located on Summit Avenue, mere minutes from the Garden State Parkway.

Peter T. Meinke will take the Tri-I TDI into the next phase of growth.

The combination of taselisib and fulvestrant has shown to slow the growth of cancer in post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2) negative, PIK3CA-mutant, inoperable, locally advanced or metastatic breast cancer. Researchers from Memorial Sloan Kettering Cancer Center (MSK) presented this data, from the SANDPIPER trial, in a press conference at the annual meeting of the American Society of Clinical Oncology. This combination of a mutant-selective PI3K inhibitor and a selective estrogen receptor degrader halted the growth of advanced breast cancer for two months longer than hormone therapy alone and decreased the chance of cancer worsening by 30 percent.

Microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies can predict Lynch syndrome (LS) across tumor types, according to researchers from Memorial Sloan Kettering Cancer Center (MSK), who presented this retrospective data analysis in a press conference at the annual meeting of the American Society of Clinical Oncology. This finding suggests that LS is linked to more types of cancer than previously thought, prompting a call for germline testing for LS in all individuals with MSI-high (MSI-H)/mismatch repair deficient (MMR-D) tumors.

Researchers at Memorial Sloan Kettering (MSK) reported results, which were highlighted at the American Society of Clinical Oncology (ASCO) press cast, that eight weeks of acupuncture or cognitive behavioral therapy for insomnia (CBT-I) decreased the severity of insomnia in cancer survivors. While both acupuncture and CBT-I resulted in clinically meaningful and durable effects among this group, CBT-I was more effective, especially among people with mild insomnia symptoms.

Researchers at Memorial Sloan Kettering (MSK) report that firefighters at the World Trade Center (WTC) scene in September 2001 were nearly twice as likely as the general population to have a multiple myeloma precursor condition called monoclonal gammopathy of undetermined significance (MGUS). This new research was published online today in JAMA Oncology.

Memorial Sloan Kettering Cancer Center (MSK) has announced that Debra Berns has been named as MSK’s Senior Vice President and Chief Risk Officer following an extensive national search.

Memorial Sloan Kettering Cancer Center has recruited Sohrab Shah, PhD, to serve as the inaugural Chief of Computational Oncology within the Department of Epidemiology and Biostatistics. In this role, Dr. Shah will lead the effort to build a research program dedicated to harnessing MSK’s numerous “Big Data” resources to translate biologic knowledge to clinical practice.

The combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®) has shown improved progression-free survival (PFS) compared with chemotherapy as a first-line treatment for people with a high tumor mutational burden (TMB) in advanced non-small cell lung cancer (NSCLC). Data from the CheckMate -227 trial is being reported by Matthew Hellmann, MD, of Memorial Sloan Kettering Cancer Center, at the AACR Annual Meeting 2018. This research is featured in the meeting’s press program, and findings are being presented in the Clinical Trials Plenary Session, “Immunotherapy Combinations: The New Frontier in Lung Cancer.”

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) significantly increased overall survival versus treatment with sunitinib (Sutent®) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) that were reported online today in the New England Journal of Medicine.